Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Laboratory analyzer workflow interface, 9/13

The IVD Industry Connectivity Consortium (IICC) has developed a laboratory analyzer workflow (LAW) interface, which is a global interface based on a common set of clinical laboratory communications that unambiguously define communication protocols. In 2012, four diagnostic and three IT companies successfully validated 129 LAW tests. Since then, IICC has refined these interfaces and is asking more manufacturers to adopt the standard in an effort to simplify connectivity in the clinical laboratory and within the health care enterprise. Benefits of

Reference solutions for bath salt metabolites, 9/13

Cerilliant offers seven new certified spiking solutions of bath salt metabolites. The new products are 1.0 mg/mL (as free base) in methanol for the primary urinary metabolites of bath salt cathinones, mephedrone, buphedrone, pentedrone, flephedrone, N-ethylcathinone, and 4-methylethcathinone. For GC/MS and LC/MS methods that quantify concentrations of synthetic cathinone metabolites, the company also offers the corresponding deuterium-labeled internal standard. Cerilliant offers certified Snap-N-Spike solutions for use in clinical toxicology applications, medication monitoring, forensic analysis, employee drug screening, and urine drug

Reference solutions for thyroid hormones, 9/13

Cerilliant offers certified Snap-N-Spike solutions of thyroid hormones T4, T3, and reverse T3 at concentrations of 100 µg/mL in 0.1 N ammonia in methanol for each solution standard. These certified spiking solutions are for use as critical starting materials in the preparation of calibrators, controls, or linearity standards for analytical testing including LC-MS/MS analysis of free and total thyroid hormone levels. Comprehensive certificates of analysis (COAs) come with every Cerilliant certified reference standard and include all analytical data from full

Sanger sequencing system and HLA typing kits, 9/13

Life Technologies in February received FDA 510(k) clearance for its 3500 Dx genetic analyzers and SeCore HLA typing kits. The company’s 7500 Fast Dx real-time PCR system was cleared for diagnostic use with the CDC’s H1N1 assay in 2008. The Applied Biosystems 3500 Dx/3500xL Dx CS2 genetic analyzers, Invitrogen SeCore HLA sequencing kits, and uType Dx HLA sequence analysis software constitute the first FDA 510(k)-cleared sequence-based system for HLA typing in the United States. HLA typing on the 3500 Dx

General-purpose reagents, 9/13:80 (AACC)

NanoString Technologies’ nCounter Elements are digital molecular bar-coding chemistry assay components that allow users to assemble their own assays with oligonucleotide probes that target their genes of interest. The components enable highly multiplexed, direct profiling of individual molecules in a single reaction without amplification and are effective for a range of applications requiring efficient, high-precision quantitation of tens to hundreds of target molecules across a sample set. This chemistry generates high-quality results from challenging sample types, such as FFPE tissue

C. diff assay and PCR system, 9/13:78 (AACC)

Quidel Corp. and Life Technologies in March received FDA 510(k) clearances to market the Quidel Molecular Direct C. difficile assay with Life Technologies’ QuantStudio Dx and 7500 Fast Dx Applied Biosystems real-time PCR instruments. The C. difficile assay is part of Quidel’s molecular diagnostic product line, which includes PCR reagent kits for molecular diagnostic laboratories including Life Technologies’ QuantStudio Dx and 7500 Fast Dx. These reagents can be refrigerated instead of frozen, are convenient and ready to use, and provide a

NGS analytics software, 9/13:78 (AACC)

Life Technologies’ Oncomine Next-Gen Sequencing Power Tools is an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next-generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed. Oncomine NGS Power Tools constitute a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancer types,

Automated ESR analysis system, 9/13:78 (AACC)

Through a distribution agreement with Alifax, Beckman Coulter and Iris Diagnostics have launched the Alifax automated erythrocyte sedimentation rate (ESR) analysis system. The automated ESR analysis systems are designed to fit the workloads of small hospitals, large reference laboratories, core laboratories, and satellite locations. The ESR system increases productivity, improves efficiencies in laboratory labor use, and reduces turnaround times. The Alifax ESR system provides fully automated, hands-off operation in a small footprint and processes the same whole blood tubes from

HbA1c test, 9/13 (AACC)

Beckman Coulter’s FDA-approved hemoglobin A1c assay (HbA1c) with improved performance is for standard use on the company’s UniCel DxC systems. The HbA1c reagent was designed and developed to improve accuracy and precision, to continue to meet the latest accuracy grading from the College of American Pathologists and the recommendations of the National Glycohemoglobin Standardization Program and International Federation of Clinical Chemistry. The assay features ready-to-use liquid reagents for A1c and total hemoglobin; a five-level calibrator set; 30-day onboard reagent stability;

Troponin I assay, 9/13:76 (AACC)

Beckman Coulter’s FDA-cleared Access AccuTnI+3 troponin I assay is available for use on the company’s Access 2 immunoassay system. In accordance with FDA requirements, the company conducted a large multicenter prospective clinical trial on the AccuTnI+3 troponin I assay that enrolled more than 1,900 subjects. The trial confirmed that the assay provides the clinical performance necessary for optimal patient management. The data from the trial show that the assay delivers the precision, clinical sensitivity, and clinical specificity necessary to assist

MARKETPLACE

TRENDING